Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis
NCT07388420Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised trial of evolocumab in acute pancreatitis (AP) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoints: Triglyceride levels at 7 days and Rate of achieving target triglyceride levels at 7 days. Started Jan 2026; status: recruiting.
02
Drugs
evolocumab
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT07388420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388420.